Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of ALKS 2680 in narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia
2024-519822-18-00Phase 3Authorised
- Sponsor
- Alkermes
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, open-label trial of alixorexton in narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and hypersomnolence disorder (2 arms), sponsored by Alkermes. Primary endpoint: Treatment-emergent adverse events. Planned start May 2025; status: authorised.
02
Drugs
alixorexton
03
Conditions
narcolepsy type 1 (NT1)narcolepsy type 2 (NT2)hypersomnolence disorder
Beyond the preview
Go deeper on 2024-519822-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519822-18-00.